title: One-year clinical outcome of patients treated with or without abciximab in rescue coronary angioplasty.
abstract: BACKGROUND
  The clinical results of abciximab administration during rescue angioplasty (PCI) are poorly investigated.
  
  
  METHODS
  We evaluated the outcome of 406 consecutive patients undergoing rescue PCI treated with (n=218) or without (n=188) abciximab and a clopidogrel loading dose of 300 mg. The end point was the incidence of major cardiac adverse events (MACE) defined as death, recurrent acute myocardial infarction (AMI) and target vessel revascularization at 30 days and 1 year. The predictors of MACE were also investigated.
  
  
  RESULTS
  No differences were found in MACE between the groups treated with or without abciximab at 30 days (15 and 20, p=0.67) and 1 year (23 and 29, p=0.85). Stepwise logistic regression analysis identified: cardiogenic shock (Odds Ratio [OR]=17.8, 95% confidence interval [CI] 5-99, p=0.0001), age (OR=1.099, 95% CI 1.04-1.15, p=0.0001), TIMI flow 0-1 after procedure (OR=5.51, 95% CI 1.72-17.6, p=0.004) as independent predictors of MACE at 30 days. Cox proportional hazards model identified: cardiogenic shock (adjusted hazard ratio [HR]=3.83, 95% confidence interval [CI] 1.76-8.35, p=0.01), age (HR=3.7, 95% CI 1.75-8.3, p=0.01), TIMI flow 0-1 after procedure (HR=1.04, 95% CI 1.01-1.07, p=0.001 as predictors of MACE at 1 year). After propensity score adjustments the predictors of MACE did not change.
  
  
  CONCLUSIONS
  There were no differences in MACE at 30 days and 1 year in patients treated with or without abciximab during rescue PCI after a clopidogrel loading dose of 300 mg. Cardiogenic shock, age and TIMI flow 0 and 1 after PCI were predictors of MACE.
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy. Electronic address: f.defelice@lycos.com.
authors.forename: Francesco
authors.initials: F
authors.lastname: De Felice
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy.
authors.forename: Rosario
authors.initials: R
authors.lastname: Fiorilli
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Parma
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy.
authors.forename: Carmine
authors.initials: C
authors.lastname: Musto
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy.
authors.forename: Marco Stefano
authors.initials: MS
authors.lastname: Nazzaro
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy.
authors.forename: Pierpaolo
authors.initials: P
authors.lastname: Confessore
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Scappaticci
authors.affiliation: UO Cardiologia Interventistica Azienda ASL S. Camillo Forlanini Circonvallazione Gianicolense n 87, 00152 Roma, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Violini
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000639:trends*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab